<i>IDH1/2</i>but not<i>DNMT3A</i>mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Claude Preudhomme, Alice Marceau‐Renaut et al.|Oncotarget|2015Cited by 98
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemiaJean‐Emmanuel Bibault, Claude Preudhomme, Martin Figeac et al.|Oncotarget|2015Cited by 57